Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
Question
Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
Direct answer
Novartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile. — bullish pressure on NVS.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis”, revision 1, evidence through 2026-09-01. https://marketontology.com/catalysts/2026-09-01/novartis-reports-positive-phase-iii-results-for-remibrutinib-in-multiple-scleros-6bc1ac
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| NVS | ▲Bull | 1–3 months | Catalyst Driven | 73 |
Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
Novartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile. — bullish pressure on NVS.
Novartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile.
- SummaryNovartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile.
- NVSDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- NVS closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- NVS price vs. pre-event level
- NVS volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS RPRX-11.45%
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary EndpointNVS RPRX
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS-11.45%
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointNVS
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.